Prednisolone Steaglate

Prednisolone Steaglate

SCHEMBL136864

CCCCCCCCCCCCCCCCCC(=O)OCC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 8/20 0.77
LMNA P02545 2/20 0.77
PGR P06401 4/20 0.74
SMN1; SMN2 Q16637 2/20 0.72
POLB P06746 1/20 0.72
GAA P10253 1/20 0.72
MAPT P10636 1/20 0.72
NR3C1 P04150 8/20 0.67
CYP3A4 P08684 3/20 0.67
HSD17B10 Q99714 2/20 0.67
AR P10275 2/20 0.67
ABCB11 O95342 1/20 0.67
TNF P01375 1/20 0.67
IL6 P05231 1/20 0.67
SERPINA6 P08185 1/20 0.67
NR3C2 P08235 1/20 0.67
GLUL P15104 1/20 0.67
ADAM17 P78536 1/20 0.67
GPBAR1 Q8TDU6 1/20 0.67
CYP2C19 P33261 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7145316 0.98 HIF1A (0.79) HIF1ALMNAPGRSMN1; SMN2POLB
SCHEMBL7613021 0.98 HIF1A (0.79) HIF1ALMNAPGRSMN1; SMN2POLB
SCHEMBL7142738 0.98 HIF1A (0.79) HIF1ALMNAPGRSMN1; SMN2POLB
SCHEMBL11090884 0.98 HIF1A (0.79) HIF1ALMNAPGRSMN1; SMN2POLB
SCHEMBL7985 0.98 HIF1A (0.80) HIF1ALMNAPGRSMN1; SMN2POLB
SCHEMBL677625 0.96 HIF1A (0.82) HIF1ALMNAPGRSMN1; SMN2POLB
SCHEMBL10363483 0.96 HIF1A (0.82) HIF1ALMNAPGRSMN1; SMN2POLB
SCHEMBL6715060 0.94 HIF1A (0.73) HIF1ALMNAPGRSMN1; SMN2POLB
Prednisolone Acetate SCHEMBL9838659 0.93 HIF1A (0.86) HIF1ALMNAPGRSMN1; SMN2POLB
SCHEMBL16018292 0.93 HIF1A (0.85) HIF1ALMNAPGRSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 666 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12364682-B2 Use of tegaserod in preparation of anti-tumor drug QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) 2025-07-22 US claimed
US-20120058979-A1 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS ZALICUS INC. (US) 2012-03-08 US claimed
US-20120028910-A1 STORAGE-STABLE AQUEOUS OPHTHALMIC FORMULATIONS FOVEA PHARMACEUTICALS (FR) 2012-02-02 US claimed
US-8080553-B2 Methods and reagents for the treatment of immunoinflammatory disorders ZALICUS INC. (US) 2011-12-20 US claimed
EP-2301628-A1 Methods and reagents for the treatment of immunoinflammatory disorders Zalicus Inc. (US) 2011-03-30 EP claimed
EP-2205248-A2 COMBINATION OF NITRODERIVATIZED STEROID AND BRONCHODILATOR FOR TREATING RESPIRATORY DISEASE Nicox S.A. (FR) 2010-07-14 EP claimed
EP-2070550-A1 Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases Combinatorx, Incorporated (US) 2009-06-17 EP claimed
WO-2009071990-A2 NO-DONATING CORDICOSTEROID WITH IMPROVED PHARMACOKINETIC, ANTI-INFLAMMATORY AND VASODILATORY PROPERTIES TOPIGEN PHARMACEUTICALS INC. (US) 2009-06-11 WO claimed
US-20090087425-A1 Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease TOPIGEN PHARMACEUTICALS INC. (CA) 2009-04-02 US claimed
US-20090088411-A1 No-donating corticosteroid with improved pharmacokinetic, anti-inflammatory and vasodilatory properties TOPIGEN PHARMACEUTICALS INC. (CA) 2009-04-02 US claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0900233-A1 NOVEL STEROID NITRITE AND NITRATE ESTER DERIVATIVES USEFUL AS ANTI-INFLAMMATORY DRUGS G.D. SEARLE & CO. (US) 1999-03-10 EP claimed
EP-0786999-A4 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO INC (US) 1999-01-20 EP claimed
EP-0792371-A4 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO INC (US) 1998-12-30 EP claimed
WO-1997041144-A1 NOVEL STEROID NITRITE AND NITRATE ESTER DERIVATIVES USEFUL AS ANTI-INFLAMMATORY DRUGS G.D. SEARLE & CO. (US) 1997-11-06 WO claimed
EP-0792371-A1 COMBINATION METHOD FOR ACNE TREATMENT Merck & Co., Inc. (US) 1997-09-03 EP claimed
EP-0786999-A1 COMBINATION METHOD FOR ACNE TREATMENT Merck & Co., Inc. (US) 1997-08-06 EP claimed
WO-1996012817-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
WO-1996012487-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
EP-0496520-A1 Novel bone acting agents MERCK & CO. INC. (US) 1992-07-29 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12364682-B2 Use of tegaserod in preparation of anti-tumor drug STAT3, JAK2, JAK1 HIF1A 4476/4885LMNA 4823/4885PGR 2826/4885
US-20090088411-A1 No-donating corticosteroid with improved pharmacokinetic, anti-inflammatory and vasodilatory properties NOS1, NOS2, NOS3 HIF1A 268/4885LMNA 3321/4885PGR 557/4885
US-20090087425-A1 Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease HSD11B1, HSD11B2, CYP11B1 HIF1A 1235/4885LMNA 3384/4885PGR 1152/4885
US-20120058979-A1 METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS IL5, TPMT, TSLP HIF1A 1602/4885LMNA 3888/4885PGR 2470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.